High False-Positive Rate of (1,3)-β-D-Glucan in Onco-Hematological Patients Receiving Immunoglobulins and Therapeutic Antibodies.

Tschopp, J.; Brunel, A.S.; Spertini, O.; Croxatto, A.; Lamoth, F.; Bochud, P.Y.

doi:10.1093/cid/ciab1028

High False-Positive Rate of (1,3)-β-D-Glucan in Onco-Hematological Patients Receiving Immunoglobulins and Therapeutic Antibodies.

Details

Request a copy

Serval ID

serval:BIB_D7EA460AD1EC

Type

Article: article from journal or magazin.

Collection

Publications

Institution

UNIL/CHUV

Title

High False-Positive Rate of (1,3)-β-D-Glucan in Onco-Hematological Patients Receiving Immunoglobulins and Therapeutic Antibodies.

Journal

Clinical infectious diseases

Author(s)

Tschopp J., Brunel A.S., Spertini O., Croxatto A., Lamoth F., Bochud P.Y.

ISSN

1537-6591 (Electronic)

ISSN-L

1058-4838

Publication state

Published

Issued date

25/08/2022

Peer-reviewed

Oui

Volume

Number

Pages

330-333

Language

english

Notes

Publication types: Journal Article
Publication Status: ppublish

Abstract

Immunoglobulins and/or therapeutic antibody preparations are associated with a high rate of false-positive (1,3)-β-D-glucan (BDG) tests in onco-hematological patients routinely screened for fungal infections. The benefit of BDG monitoring shall be balanced against the risk of false-positive tests leading to unnecessary investigations and costs in this population.

Keywords

Glucans, Humans, Immunoglobulins, Proteoglycans, Sensitivity and Specificity, beta-Glucans, false-positive, intravenous immunoglobulines, onco-hematology, therapeutic antibodies, β-D-glucan

OAI-PMH

oai:serval.unil.ch:BIB_D7EA460AD1EC

DOI

10.1093/cid/ciab1028

Pubmed

34996098

Web of science

000756967700001

Open Access

Yes

Create date

10/01/2022 9:25